FreshPatents.com Logo

new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Merck Sharp x26 Dohme Corp
Merck Sharp x26 Dohme Corporation
Merck Sharp x26 Dohme Corp And Northwestern University
Merck Sharp x26 Dohme Corp_20131212

Popular
Companies


Web
Adobe patents
Akamai patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Ticker Symbols

Merck Sharp & Dohme Corp patents


      
Recent patent applications related to Merck Sharp & Dohme Corp. Merck Sharp & Dohme Corp is listed as an Agent/Assignee. Note: Merck Sharp & Dohme Corp may have other listings under different names/spellings. We're not affiliated with Merck Sharp & Dohme Corp, we're just tracking patents.

ARCHIVE: New 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Merck Sharp & Dohme Corp-related inventors



Search recent Press Releases: Merck Sharp & Dohme Corp-related press releases
Count Application # Date Merck Sharp & Dohme Corp patents (updated weekly) - BOOKMARK this page
12012025303210/04/12Novel cationic lipids with short lipid chains for oligonucleotide delivery
22012020281908/09/12Combination therapy using a beta 3 adrenergic receptor agonists and an antimuscarinic agent
32014020656307/24/14 new patent  Biomarkers for psoriasis
42014020664007/24/14 new patent  2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
52014020664107/24/14 new patent  Remedy
62014020666507/24/14 new patent  Selective glycosidase inhibitors and uses thereof
72014020667507/24/14 new patent  Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
82014020671507/24/14 new patent  Preparation and use of compounds as protease inhibitors
92014020018007/17/14Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens
102014020021307/17/142-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
112014017015406/19/14Engineered anti-il-23r antibodies
122014017065806/19/14Mammalian cytokines; related reagents
132014017143706/19/14Oxazole derivatives useful as inhibitors of faah
142014017145606/19/14Fused tricyclic compounds as mtor inhibitors
152014017148006/19/14Crystalline polymorphic forms of an antidiabetic compound
162014016177006/12/142'-cyano substituted nucleoside derivatives and methods of use thereof useful for the treatment of viral diseases
172014016179806/12/14Anti-pcsk9 and methods for treating lipid and cholesterol disorders
182014014744205/29/14Use of il-23 antagonists for treatment of infection
192014014746105/29/14Polypeptides for inducing a protective immune response against staphylococcus aureus
202014014095405/22/14Methods of modulating cytokine activity; related reagents
212014014101205/22/14Engineered anti-tslp antibody
222014014144405/22/14Isolated mammalian monocyte cell genes; related reagents
232014014144505/22/14Isolated mammalian monocyte cell genes; related reagents
242014014211505/22/14Inhibitors of the renal outer medullary potassium channel
252014014095405/22/14Methods of modulating cytokine activity; related reagents
262014014101205/22/14Engineered anti-tslp antibody
272014014144405/22/14Isolated mammalian monocyte cell genes; related reagents
282014014144505/22/14Isolated mammalian monocyte cell genes; related reagents
292014014211505/22/14Inhibitors of the renal outer medullary potassium channel
302014012836105/08/14Cyclic amide bace-1 inhibitors having a benzamide substituent
312014012836705/08/14Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
322014012836805/08/14Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
332014012836105/08/14Cyclic amide bace-1 inhibitors having a benzamide substituent
342014012836705/08/14Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
352014012836805/08/14Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
362014012003705/01/14Method for detection of amyloids beta oligomers in a fluid sample and uses thereof
372014012003705/01/14Method for detection of amyloids beta oligomers in a fluid sample and uses thereof
382014011291904/24/14Interleukin-10 antibodies
392014011392004/24/14Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
402014011291904/24/14Interleukin-10 antibodies
412014011392004/24/14Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
422014010588704/17/14Methods for modulating il-33 activity
432014010641304/17/14Immobilized transaminases and process for making and using immobilized transaminase
442014010734604/17/14Process for preparing chiral dipeptidyl peptidase-iv inhibitors
452014010588704/17/14Methods for modulating il-33 activity
462014010641304/17/14Immobilized transaminases and process for making and using immobilized transaminase
472014010734604/17/14Process for preparing chiral dipeptidyl peptidase-iv inhibitors
482014009356404/03/14Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with simvastatin
492014009387504/03/14Mammalian cytokines; receptors; related reagents and methods
502014009356404/03/14Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with simvastatin
512014009387504/03/14Mammalian cytokines; receptors; related reagents and methods
522014008804803/27/14Diazeniumdiolate cyclohexyl derivatives
532014008804803/27/14Diazeniumdiolate cyclohexyl derivatives
542014008088403/20/14Novel crystalline forms of a dipeptidyl peptidase-iv inhibitor
552014008088403/20/14Novel crystalline forms of a dipeptidyl peptidase-iv inhibitor
562014005789302/27/14Substituted cycloproply compounds, compositions containing such compounds and methods of treatment
572014005174002/20/14Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
582014004574602/13/14Antidiabetic tricyclic compounds
592014004582902/13/14Substituted 1,3-benzothiazol-2(3h)-ones and [1,3]thiazolo[5,4-b]pyridin-2(1h)-ones as positive allosteric modulators of mglur2
602014004583202/13/14Insulin-like growth factor-1 receptor inhibitors
612014003762702/06/14Modulation of pilr receptors to treat microbial infections
622014003894202/06/14Rorgammat inhibitors
632014003897002/06/14Bridged and fused antidiabetic compounds
642014003025501/30/14Methods of predicting cancer cell response to therapeutic agents
652014003076001/30/14Pavec
662014003125101/30/14Methods of classifying human subjects with regard to cancer prognosis
672014003134901/30/14Inhibitors of the renal outer medullary potassium channel
682014002366701/23/14Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
692014000518201/02/14Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
702013034451212/26/13Cd16a reporter assay for evaluation of adcc potential of biologics
712013033137212/12/13Cyclic amine substituted oxazolidinone cetp inhibitor
722013033137212/12/13Cyclic amine substituted oxazolidinone cetp inhibitor
732013032323912/05/13Modulation of pilr receptors to treat sepsis
742013032324612/05/13Use of mdl-1 antagonists to treat spondylarthropathy
752013032325112/05/13Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
762013032448312/05/13Mammalian cell surface antigens; related reagents
772013032461012/05/13Cathepsin cysteine protease inhibitors
782013032472812/05/13Process for the preparation of an orexin receptor antagonist
792013031635411/28/13Mammalian cytokine; related reagents
802013029627811/07/13Diazeniumdiolate derivatives
812013028776310/31/13Combination therapy for treating cancer comprising an igf-1r inhibitor and an akt inhibitor
822013028021410/24/13Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases
832013028147410/24/13Fused tricyclic inhibitors of mammalian target of rapamycin
842013026114010/03/13Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
852013025167709/26/13Genetic markers associated with interferon-alpha response
862013024369209/19/13Fdg-pet evaluation of ewing's sarcoma sensitivity
872013023751809/12/13Novel compounds that are erk inhibitors
882013023085509/05/13Monocyte-derived nucleic acids and related compositions and methods
892013022558208/29/13Biaryl-spiroaminooxzaoline analogues as alpha 2c adrenergic receptor modulators
902013022583608/29/13Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
912013022558208/29/13Biaryl-spiroaminooxzaoline analogues as alpha 2c adrenergic receptor modulators
922013022583608/29/13Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
932013021657508/22/13Recombinant subunit dengue virus vaccine
942013021769508/22/13Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
952013021775608/22/13Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
962013021776608/22/13Formulations for cathepsin k inhibitors
972013021657508/22/13Recombinant subunit dengue virus vaccine
982013021769508/22/13Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
992013021775608/22/13Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
1002013021776608/22/13Formulations for cathepsin k inhibitors
1012013020306008/08/13Mammalian genes; related reagents
1022013020306008/08/13Mammalian genes; related reagents
1032013018927807/25/13Antagonists of pcsk9
1042013018927807/25/13Antagonists of pcsk9
1052013015794006/20/13Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
1062013015672906/20/13Mammalian receptor proteins; related reagents and methods
1072013015677106/20/13Fdf03 antibodies and uses thereof
1082013015794006/20/13Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
1092013015672906/20/13Mammalian receptor proteins; related reagents and methods
1102013015677106/20/13Fdf03 antibodies and uses thereof
1112013015036206/13/13Novel pyrazolo[1,5-a]pyrimidine derivatives as mtor inhibitors
1122013015036206/13/13Novel pyrazolo[1,5-a]pyrimidine derivatives as mtor inhibitors
1132013014385906/06/13Novel prolylcarboxypeptidase inhibitors
1142013014385906/06/13Novel prolylcarboxypeptidase inhibitors
1152013013104105/23/13Spirocyclic compounds
1162013013104205/23/13Spiroxazolidinone compounds
1172013013104105/23/13Spirocyclic compounds
1182013013104205/23/13Spiroxazolidinone compounds
1192013012200905/16/13Engineered anti-il-23p19 antibodies
1202013012320005/16/13Mammalian cell surface antigens; related reagents
1212013012323705/16/13Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
1222013012200905/16/13Engineered anti-il-23p19 antibodies
1232013012320005/16/13Mammalian cell surface antigens; related reagents
1242013012323705/16/13Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
1252013011522305/09/13Antagonists of pcsk9
1262013011623105/09/13Tyrosine kinase inhibitors
1272013011522305/09/13Antagonists of pcsk9
1282013011623105/09/13Tyrosine kinase inhibitors
1292013010973905/02/13Compositions and methods for short interfering nucleic acid inhibition of nav1.8
1302013009605304/18/13Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin
1312013007139003/21/13Method for preparing antibodies having improved properties
1322013006481703/14/13Engineered anti-il-23r antibodies
1332013005985003/07/13Aza-indole derivatives useful as modulators of faah
1342013005335202/28/13Diazeniumdiolate cyclopentyl derivatives
1352013004591402/21/13Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators
1362013004092902/14/13Novel prolylcarboxypeptidase inhibitors
1372013004093202/14/13Substituted aryl sulfone derivatives as calcium channel blockers
1382013003456102/07/13Isolated mammalian monocyte cell genes; related reagents
1392013003531202/07/13Cathepsin cysteine protease inhibiors
1402013002351501/24/13Novel spiropiperidine prolylcarboxypeptidase inhibitors
1412013001804801/17/13Oxazole derivatives useful as modulators of faah
1422013001252601/10/13Oxazole derivatives useful as modulators of faah
1432013000579701/03/13Endosomolytic poly(amidoamine) disulfide polymers for the delivery of oligonucleotides
1442013000451801/03/13Cyclic amine bace-1 inhibitors having a benzamide substituent
1452012032967912/27/12Eukaryotic cell display systems
1462012031532112/13/12Immunological methods and compositions for the treatment of alzheimer's disease
1472012031620012/13/12Pyridone derivatives
1482012027724011/01/12Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
1492012026477710/18/12Oxadiazole beta carboline derivatives as antidiabetic compounds
1502012023200709/13/12Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens
1512012023208609/13/12Fused tricyclic compounds with adenosine a2a receptor antagonist activity
1522012022588609/06/12Novel pyrrolidine derived beta 3 adrenergic receptor agonists
1532012021484608/23/12Hexahydrocyclopentyl[f]indazole pyridyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
1542012021484708/23/122-[1-phenyl-5-hydroxy-4a-substituted-hexahydrocyclopenta[f]indazol-5-yl]ethyl phenyl derivatives as glucocorticoid receptor ligands
1552012020188508/09/12Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
1562012019690108/02/12Tertiary amide orexin receptor antagonists
1572012019070107/26/12Renin inhibitors
1582012017868107/12/12Bipiperidinyl compounds, compositions, containing such compounds and methods of treatment
1592012017875007/12/12Niacin receptor agonists, compositions containing such compounds and methods of treatment
1602012017239707/05/12Hexahydrocyclopenta[f]indazole 5-yl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
1612012016415806/28/12Anti-addl monoclonal antibody and use thereof
1622012015743806/21/12Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
1632012015743206/21/12Novel pyrrolidine derived beta 3 adrenergic receptor agonists
1642012014277006/07/12Pharmaceutical compositions of hdac inhibitors and chelatable metal compounds, and metal-hdac inhibitor chelate complexes
1652012014269406/07/12Substituted 4-hydroxypyrimidine-5-carboxamides
1662012014275206/07/12Hiv protease inhibitors
1672012013601205/31/12Amino tetrahydro-pyridopyrimidine pde10 inhibitors
1682012012162405/17/12Hepatitis c virus ns3 protease inhibitors
1692012011913005/17/12Diaphragm valve with improved sealing performance and leak detection
1702012012150805/17/12Radiolabeled cgrp antagonists
1712012012158005/17/12Methods for producing high concentration lyophilized pharmaceutical formulations
1722012012289905/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
1732012012290005/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
1742012012291105/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
1752012011589405/10/12Imidazole derivatives useful as modulators of faah and as faah imaging agents
1762012011592105/10/12Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment
1772012010860005/03/12Substituted 4-hydroxypyrimidine-5-carboxamides
1782012009500104/19/12Substituted-1,3,8-triazaspiro[4.5]decane-2,4-diones
1792012009505504/19/12Hexahydrocyclopentyl[f]indazole 5-hydroxymethyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
1802012008348304/05/12Inhibitors of hepatitis c virus replication
1812012008267904/05/12Antagonists of pcsk9
1822012008268004/05/12Antagonists of pcsk9
1832012007679903/29/12Antagonists of pcsk9
1842012007796403/29/12Antagonists of pcsk9
1852012005318103/01/12Pyrrolidine-derived beta 3 adrenergic receptor agonists
1862012004097802/16/12Heterocyclic fused cinnoline m1 receptor positive allosteric modulators
1872012003460802/09/12Microrna as a biomarker of pancreatic islet beta-cell engagement
1882012003521402/09/12Renin inhibitors
1892012003524702/09/12Rna interference mediated inhibition of signal transducer and activator of transcription 6 (stat6) gene expression using short interfering nucleic acid (sina)
1902012002894002/02/12Functionally selective azanitrile alpha-2c adrenoreceptor agonists
1912012002905402/02/12Rna interference mediated inhibition of gata binding protein 3 (gata3) gene expression using short intefering nucleic acid (sina)
1922012002214301/26/12Rna interference mediated inhibition of the thymic stromal lymphopoietin (tslp) gene expression using short interfering nucliec acid (sina)
1932012002107401/26/12P2x3, receptor antagonists for treatment of pain
1942012002194801/26/12Surface display of whole antibodies in eukaryotes
1952012002214201/26/12Rna interference mediated inhibition of signal transducer and activator of transcription 1 (stat1) gene expression using short interfering nucleic acid (sina)
1962012001601001/19/12Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach1) gene expression using short interfering nucleic acid (sina)
1972012001601101/19/12Rna interference mediated inhibition of connective tissue growth factor (ctgf) gene expression using short interfering nucleic acid (sina)
1982012000958001/12/12Methods for quantitating small rna molecules
1992012001019301/12/12Cgrp receptor antagonists
2002012001027201/12/12Rna interference mediated inhibition of apoptosis signal-regulating kinase 1 (ask1) gene expression using short interfering nucleic acid (sina)
2012012000428101/05/12Rna interference mediated inhibition of the nerve growth factor beta chain (ngfb) gene expression using short interfering nucleic acid (sina)
2022012000428201/05/12Rna interference mediated inhibition of the intercellular adhesion molecule 1 (icam-1) gene expression using short interfering nucleic acid (sina)
2032012000428001/05/12Rna interference mediated inhibition of the high affinity 1 ge receptor alpha chain (fc epsilon r1 alpha) gene expression using short interfering nucleic acid (sina)
2042011031291112/22/11Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
2052011030107912/08/11Neuromedin u receptor agonists and uses thereof
2062011029469612/01/11Methods for characterizing agonists and partial agonists of target molecules
2072011029473512/01/11Mechanism of neuromedin u action and uses thereof
2082011029477712/01/11Beta-lactamase inhibitors
2092011026353310/27/11Novel cyclic benzimidazole derivatives useful as anti-diabetic agents
2102011025059110/13/11Method of designing sirnas for gene silencing
2112011025120710/13/11Biaryl-spiroaminooxazoline analogues as alpha 2c adrenergic receptor modulators
2122011024051110/06/11Packaging for oxygen-sensitive pharmaceutical products
2132011023763409/29/11Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1
2142011022950809/22/11Polypeptides for inducing a protective immune response against staphylococcus aureus
2152011023049809/22/11Biaryl carboxamides
2162011023052609/22/11Thiazolyl mglur5 antagonists and methods for their use
2172011022419309/15/11Inhibitors of diacylglycerol acyltransferase
2182011022413409/15/11Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors
2192011022419509/15/11Heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
2202011021817409/08/11Novel cyclic benzimidazole derivatives useful as anti-diabetic agents
2212011021820209/08/11Soluble guanylate cyclase activators
2222011020773708/25/11Substituted bicyclic amines for the treatment of diabetes
2232011020794208/25/11Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]-oxepino[4,5-c]pyrrole
2242011020162108/18/11Angiotensin ii receptor antagonists
2252011019595708/11/11Substituted diazepan orexin receptor antagonists
2262011019030808/04/11Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
2272011019034608/04/11Diphenyl substituted alkanes as flap inhibitors
2282011017805907/21/111,3-oxazolidin -2-one derivatives useful as cetp inhibitors
2292011017811707/21/11Oxazolobenzimidazole derivatives
2302011017881907/21/11Devices and methods for determining a patient's propensity to adhere to a medication prescription
2312011017220507/14/11Monocyclic amide cgrp receptor antagonists
2322011015230406/23/11Spiroazaindoles
2332011013676906/09/11Method of treating men with testosterone supplement and 5alpha-reductase inhibitor
2342011012466105/26/11Oxazolobenzimidazole derivatives
2352011011833705/19/11Method of using compositions comprising mir-192 and/or mir-215 for the treatment of cancer
2362011011197605/12/11Microrna biomarkers of tissue injury
2372011011206405/12/11Pyridyl amide t-type calcium channel antagonists
2382011011207705/12/11Quinolizidinone m1 receptor positive allosteric modulators
2392011007672103/31/11Efficient production of heterologous proteins using mannosyl transferase inhibitors
2402011006566903/17/11Oxazolobenzimidazole derivatives
2412011006577803/17/11Rna interference mediated inhibition of muscarinic colinergic receptor gene expression using short interfering nucleic acid (sina)
2422011005392703/03/11Nanoparticle formation via rapid precipitation
2432011004614502/24/11Quinolizidinone m1 receptor positive allosteric modulators
2442011002151601/27/11Monocyclic cgrp receptor antagonists
2452011001586901/20/11Methods and gene expression signature for assessing growth factor signaling pathway regulation status
2462010033017712/30/10Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
2472010032402312/23/10Imidazobenzazepine cgrp receptor antagonists
2482010032402412/23/10Quinolizidinone m1 receptor positive allosteric modulators
2492010032408812/23/10Fused pyridone m1 receptor positive allosteric modulators


ARCHIVE: New 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Merck Sharp & Dohme Corp in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Merck Sharp & Dohme Corp with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE
  
         


FreshNews promo